Key facts
- This page summarizes Joseph Vittiglio's Form 4 filing for Finch Therapeutics Group, Inc. (FNCH).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Oct 2022, 16:25.
Joseph Vittiglio - 21 Oct 2022 Form 4 Insider Report for Finch Therapeutics Group, Inc. (FNCH)
- Reporting relationship
- Chief Business & Legal Officer
- Issuer ticker
- FNCH
- Reported as of
- 21 Oct 2022
- Net transaction value
- -$5,054
- SEC form
- 4
- Accepted by SEC
- 25 Oct 2022, 16:25:29 UTC
- Prior SEC filing
- 15 Jun 2022
- Next SEC filing
- 09 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Joseph Vittiglio
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joseph Vittiglio filed Form 4 for Finch Therapeutics Group, Inc. (FNCH) on 25 Oct 2022.
Change
- Previous filing in this sequence was filed on 15 Jun 2022.
- Current net transaction value: -$5,054.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FNCH
transaction
Common Stock
Sale
- Transaction value
- $5,054
- Shares
- -3,636
- Change %
- -10%
- Price
- $1.39
- Shares after
- 31,364
- Date
- 21 Oct 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Footnote F2
Represents the weighted average price of shares sold by the broker on behalf of certain executive officers and employees of the company on October 21, 2022. The broker sold, in the aggregate on behalf of such employees, 21,137 shares in transactions ranging from $1.31 to $1.44 with a weighted average price of $1.39. The proceeds of all such sales were allocated to applicable employees on a pro rata basis based on the number of shares sold by such person. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.